314 related articles for article (PubMed ID: 32868382)
1. KDM5B Is Essential for the Hyperactivation of PI3K/AKT Signaling in Prostate Tumorigenesis.
Li G; Kanagasabai T; Lu W; Zou MR; Zhang SM; Celada SI; Izban MG; Liu Q; Lu T; Ballard BR; Zhou X; Adunyah SE; Matusik RJ; Yan Q; Chen Z
Cancer Res; 2020 Nov; 80(21):4633-4643. PubMed ID: 32868382
[TBL] [Abstract][Full Text] [Related]
2. SKP2 inactivation suppresses prostate tumorigenesis by mediating JARID1B ubiquitination.
Lu W; Liu S; Li B; Xie Y; Adhiambo C; Yang Q; Ballard BR; Nakayama KI; Matusik RJ; Chen Z
Oncotarget; 2015 Jan; 6(2):771-88. PubMed ID: 25596733
[TBL] [Abstract][Full Text] [Related]
3. KDM5B regulates the PTEN/PI3K/Akt pathway to increase sorafenib-resistance in hepatocellular carcinoma.
Liu J; Nie C
Anticancer Drugs; 2022 Oct; 33(9):840-849. PubMed ID: 35946516
[TBL] [Abstract][Full Text] [Related]
4. AKT Inhibition Modulates H3K4 Demethylase Levels in PTEN-Null Prostate Cancer.
Khan MI; Hamid A; Rath S; Ateeq B; Khan Q; Siddiqui IA; Adhami VM; Choudhry H; Zamzami MA; Mukhtar H
Mol Cancer Ther; 2019 Feb; 18(2):356-363. PubMed ID: 30446585
[TBL] [Abstract][Full Text] [Related]
5. Jarid1b promotes epidermal differentiation by mediating the repression of Ship1 and activation of the AKT/Ovol1 pathway.
Sun X; Li Z; Niu Y; Zhao L; Huang Y; Li Q; Zhang S; Chen T; Fu T; Yang T; An X; Jiang Y; Zhang J
Cell Prolif; 2019 Sep; 52(5):e12638. PubMed ID: 31152465
[TBL] [Abstract][Full Text] [Related]
6. Co-targeting SKP2 and KDM5B inhibits prostate cancer progression by abrogating AKT signaling with induction of senescence and apoptosis.
Brown LK; Kanagasabai T; Li G; Celada SI; Rumph JT; Adunyah SE; Stewart LV; Chen Z
Prostate; 2024 Jun; 84(9):877-887. PubMed ID: 38605532
[TBL] [Abstract][Full Text] [Related]
7. Crosstalking between androgen and PI3K/AKT signaling pathways in prostate cancer cells.
Lee SH; Johnson D; Luong R; Sun Z
J Biol Chem; 2015 Jan; 290(5):2759-68. PubMed ID: 25527506
[TBL] [Abstract][Full Text] [Related]
8. Depletion of SAG/RBX2 E3 ubiquitin ligase suppresses prostate tumorigenesis via inactivation of the PI3K/AKT/mTOR axis.
Tan M; Xu J; Siddiqui J; Feng F; Sun Y
Mol Cancer; 2016 Dec; 15(1):81. PubMed ID: 27955654
[TBL] [Abstract][Full Text] [Related]
9. RUNX2 overexpression and PTEN haploinsufficiency cooperate to promote CXCR7 expression and cellular trafficking, AKT hyperactivation and prostate tumorigenesis.
Bai Y; Yang Y; Yan Y; Zhong J; Blee AM; Pan Y; Ma T; Karnes RJ; Jimenez R; Xu W; Huang H
Theranostics; 2019; 9(12):3459-3475. PubMed ID: 31281490
[No Abstract] [Full Text] [Related]
10. Fumonisin B
Arumugam T; Ghazi T; Chuturgoon A
Toxins (Basel); 2020 Sep; 12(10):. PubMed ID: 33007920
[TBL] [Abstract][Full Text] [Related]
11. AKT-mediated stabilization of histone methyltransferase WHSC1 promotes prostate cancer metastasis.
Li N; Xue W; Yuan H; Dong B; Ding Y; Liu Y; Jiang M; Kan S; Sun T; Ren J; Pan Q; Li X; Zhang P; Hu G; Wang Y; Wang X; Li Q; Qin J
J Clin Invest; 2017 Apr; 127(4):1284-1302. PubMed ID: 28319045
[TBL] [Abstract][Full Text] [Related]
12. Lysine demethylase 5B suppresses CC chemokine ligand 14 to promote progression of colorectal cancer through the Wnt/β-catenin pathway.
Yan G; Li S; Yue M; Li C; Kang Z
Life Sci; 2021 Jan; 264():118726. PubMed ID: 33160990
[TBL] [Abstract][Full Text] [Related]
13. SNHG1 promotes malignant biological behaviors of glioma cells via microRNA-154-5p/miR-376b-3p- FOXP2- KDM5B participating positive feedback loop.
Li H; Xue Y; Ma J; Shao L; Wang D; Zheng J; Liu X; Yang C; He Q; Ruan X; Li Z; Liu Y
J Exp Clin Cancer Res; 2019 Feb; 38(1):59. PubMed ID: 30728054
[TBL] [Abstract][Full Text] [Related]
14. Loss of ATF3 promotes Akt activation and prostate cancer development in a Pten knockout mouse model.
Wang Z; Xu D; Ding HF; Kim J; Zhang J; Hai T; Yan C
Oncogene; 2015 Sep; 34(38):4975-84. PubMed ID: 25531328
[TBL] [Abstract][Full Text] [Related]
15. Activation of PI3K-Akt signaling pathway promotes prostate cancer cell invasion.
Shukla S; Maclennan GT; Hartman DJ; Fu P; Resnick MI; Gupta S
Int J Cancer; 2007 Oct; 121(7):1424-32. PubMed ID: 17551921
[TBL] [Abstract][Full Text] [Related]
16. PTEN inhibits BMI1 function independently of its phosphatase activity.
Fan C; He L; Kapoor A; Rybak AP; De Melo J; Cutz JC; Tang D
Mol Cancer; 2009 Nov; 8():98. PubMed ID: 19903340
[TBL] [Abstract][Full Text] [Related]
17. Discovery of a novel 1H-pyrazole- [3,4-b] pyridine-based lysine demethylase 5B inhibitor with potential anti-prostate cancer activity that perturbs the phosphoinositide 3-kinase/AKT pathway.
Cao Y; Yang P; Yang Y; Lin Z; Fan Z; Wei X; Yan L; Li Y; He Z; Ma L; Xu H; Wu C
Eur J Med Chem; 2023 May; 251():115250. PubMed ID: 36931124
[TBL] [Abstract][Full Text] [Related]
18. Interplay Among PI3K/AKT, PTEN/FOXO and AR Signaling in Prostate Cancer.
Yan Y; Huang H
Adv Exp Med Biol; 2019; 1210():319-331. PubMed ID: 31900915
[TBL] [Abstract][Full Text] [Related]
19. Clusterin enhances AKT2-mediated motility of normal and cancer prostate cells through a PTEN and PHLPP1 circuit.
Bertacchini J; Mediani L; Beretti F; Guida M; Ghalali A; Brugnoli F; Bertagnolo V; Petricoin E; Poti F; Arioli J; Anselmi L; Bari A; McCubrey J; Martelli AM; Cocco L; Capitani S; Marmiroli S
J Cell Physiol; 2019 Jul; 234(7):11188-11199. PubMed ID: 30565691
[TBL] [Abstract][Full Text] [Related]
20. Discovery of an efficacious KDM5B PROTAC degrader GT-653 up-regulating IFN response genes in prostate cancer.
Guan T; Zhang Y; Li S; Zhang W; Song Y; Li Y; He Y; Chen Y
Eur J Med Chem; 2024 Jun; 272():116494. PubMed ID: 38749268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
